PRKCB and chronic myelogenous leukemia, BCR-ABL1 positive: In a recent study, Ma and collaborators demonstrated that PKC-β overexpression was associated with resistance to TKIs and its inhibition in CML CD34+ cells increased the sensitivity to Imatinib [115].